In 2017, the entry that became Alzheimer’s Mechanism Analysis \u2014 Proof of Function #1<\/a> was written down as Invent Deposition #3325<\/strong>:<\/p>\n “My thought to amplify the core is by multiplying the board and amp mechanism operations and connections during a core connection and relay amplitude marker a starting point that has a reciprocating point to relay.”— © 2017 Christopher Gabriel Brown<\/span><\/p>\n<\/blockquote>\n The 2017 entry pointed at the mechanism in plain words, not at a marketable molecule. Between then and the Proof of Function on the storefront today, the work hardened into a structured mechanism-analysis grid: candidate aggregation pathways (tau and amyloid families), neuroinflammation drivers, and a closed-loop survey methodology that ranks each candidate against the same scoring rubric used across the cure-discovery portfolio. The grid is what a partner team receives under an evaluation licence; the underlying patent-pending filings move with full acquisition. Design targets only \u2014 no warranted clinical outcome.<\/p>\n\n
What changed between 2017 and the product on the shelf<\/h2>\n
Where it sits in the four-step framework<\/h2>\n
\n